Search

everythinglearnresearchcommunity

for

Search:↓

Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.

5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.

Taking finasteride before surgery reduces blood loss in prostate procedures.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

Finasteride treatment makes the prostate look more like a healthy one.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Some prostate cancers have gene changes that may affect treatment with certain drugs.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

Finasteride, a drug that prevents testosterone conversion, can effectively reduce blood loss in prostate surgery, especially for patients with a prostatic volume over 30 cc, and decrease post-surgery complications.

Finasteride reduces bleeding during prostate surgery.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

Injecting Platelet-Rich Plasma reduces leakage risk in colorectal surgery.

TURP specimens should be checked for various tumors, not just common prostate issues.

Androgen-driven traits don't predict prostate cancer recurrence.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

New BPH treatments have low sexual dysfunction risk but may not improve urinary symptoms as much as traditional surgery.

Higher urethral PSA levels after prostate removal may be linked to more scalp hair loss and more PSA in urethral glands.

5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.

5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.

Augmented reality improves vascular surgery by reducing risks and operation times.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Prostate surgery is often effective long-term, but some patients may need more treatment or another surgery, especially if they had prostatitis before.